Although in our model blockade of FGFR resulted in reduced neuroinflammation and enhanced synaptic and neuronal preservation in our model, anti-inflammatory effects of FGFR have been also reported: systemic administration of FGF21 reduces the inflammatory response in a stroke model (45) and intranasal administration of FGF20 reduced blood-brain-barrier impairment in severe TBI (46). The gene discussed is FGF21; the disease is stroke disorder.